1,045 Shares in Medpace Holdings, Inc. $MEDP Purchased by waypoint wealth counsel

waypoint wealth counsel purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,045 shares of the company’s stock, valued at approximately $537,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Employees Retirement System of Texas purchased a new stake in Medpace in the second quarter valued at approximately $36,000. IFP Advisors Inc grew its holdings in Medpace by 223.3% in the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after purchasing an additional 134 shares during the period. Hantz Financial Services Inc. increased its position in Medpace by 5,075.0% during the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after purchasing an additional 203 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its stake in Medpace by 514.3% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 668 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MEDP. Jefferies Financial Group boosted their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and upped their price target for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Finally, Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $490.82.

Medpace Trading Up 0.4%

NASDAQ:MEDP opened at $569.98 on Tuesday. The firm’s fifty day simple moving average is $580.13 and its 200 day simple moving average is $484.52. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The firm has a market capitalization of $16.06 billion, a price-to-earnings ratio of 39.86, a PEG ratio of 2.14 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s revenue was up 23.7% compared to the same quarter last year. During the same period last year, the company posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.